Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MK-4280A |
Synonyms | |
Therapy Description |
MK-4280A is a coformulation of MK-4280 and Pembrolizumab, which potentially induces antitumor activity (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 3584). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MK-4280A | MK4280A|MK 4280A | Immune Checkpoint Inhibitor 149 LAG3 Antibody 18 PD-L1/PD-1 antibody 122 | MK-4280A is a coformulation of MK-4280 and Pembrolizumab, which potentially induces antitumor activity (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 3584). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06036836 | Phase II | Lenvatinib + Pembrolizumab Lenvatinib + MK-4280A MK-4280A Pembrolizumab | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | Recruiting | USA | TUR | NLD | ITA | FRA | DEU | CAN | AUS | 2 |
NCT04626518 | Phase Ib/II | MK-4280A Lenvatinib + Pembrolizumab Belzutifan + Pembrolizumab MK-1308A MK-4830 + Pembrolizumab Belzutifan + Lenvatinib | Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B) | Active, not recruiting | USA | POL | NZL | NLD | ISR | HUN | GBR | FRA | ESP | CAN | AUS | 2 |
NCT04938817 | Phase Ib/II | Lenvatinib + MK-1308A MK-1308A MK-4280A MK-1308A + MK-4830 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Investigational Agents for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) | Recruiting | USA | POL | ITA | ISR | HUN | ESP | CHE | CAN | AUT | AUS | 2 |
NCT05064059 | Phase III | Regorafenib + Trifluridine-tipiracil hydrochloride MK-4280A | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) | Active, not recruiting | USA | TUR | NOR | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | AUS | 9 |
NCT04895722 | Phase II | MK-4280A MK-7684A MK-1308A MK-4830 + Pembrolizumab Pembrolizumab | Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) | Active, not recruiting | USA | TUR | ROU | POL | NLD | LTU | ITA | HUN | GRC | GBR | FRA | EST | ESP | DNK | DEU | CAN | BEL | 5 |
NCT05508867 | Phase III | Gemcitabine Bendamustine MK-4280A | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) | Recruiting | USA | TUR | SWE | POL | ISR | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUS | ARG | 4 |
NCT06395090 | Phase Ib/II | MK-7684A MK-4280 + Pembrolizumab Pembrolizumab + Vibostolimab MK-4280A | A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) | Recruiting | USA | 2 |